Is viberzi safe for ibs d patients?

Risks of Viberzi in IBS-D Patients

Viberzi, also known as eluxadoline, is a medication used to treat irritable bowel syndrome with diarrhea (IBS-D) in adults. While Viberzi has shown promise in reducing diarrhea in IBS-D patients, concerns about its safety have been raised due to potential risks, particularly related to pancreatitis and sphincter of Oddi dysfunction.

Pancreatitis Risk: Viberzi has been associated with an increased risk of pancreatitis, a serious and potentially life-threatening condition. According to the FDA, Viberzi was withdrawn from the market in 2018 due to this risk [1]. Patients taking Viberzi should be monitored for symptoms of pancreatitis, such as severe abdominal pain, nausea, and vomiting.

Sphincter of Oddi Dysfunction: Viberzi can also cause sphincter of Oddi dysfunction, a rare but potentially serious condition that can lead to pancreatitis. This risk is particularly concerning in patients with pre-existing sphincter of Oddi dysfunction [2].

Adverse Effect Profile: The most common adverse effects associated with Viberzi include nausea, vomiting, and stomach pain. Less common but serious side effects may include pancreatitis, sphincter of Oddi dysfunction, and hypersensitivity reactions [3].

IBS-D Patient Population: Patients with IBS-D may be at increased risk for adverse effects due to Viberzi. This population often experiences complex symptoms, and the use of Viberzi should be carefully evaluated on a case-by-case basis by healthcare professionals.

Regulatory Actions: The FDA issued a boxed warning in 2017 to highlight the risks associated with Viberzi. The agency also required the manufacturer to conduct a clinical trial to further evaluate the safety of the medication in IBS-D patients.

Alternative Treatment Options: For patients with IBS-D, alternative treatment options are available that may be safer or more tolerable. These may include medications like linaclotide, lubiprostone, or rifaximin, which have a different mechanism of action and a more favorable adverse effect profile.

In summary, while Viberzi has shown promise in treating IBS-D, its use is associated with significant risks, particularly pancreatitis and sphincter of Oddi dysfunction. Patients should be carefully evaluated for the potential benefits and risks of Viberzi by a healthcare professional before initiating treatment.

Sources:

[1] FDA (2018). Eluxadoline (marketed as Viberzi) Safety Alert: Serious liver damage.

[2] DrugPatentWatch.com (2023). Eluxadoline (Viberzi) patents.

[3] UpToDate (2023). Eluxadoline: Drug information.

References:

* DrugPatentWatch.com: https://www.drugpatentwatch.com/
* FDA: https://www.fda.gov/
* UpToDate: https://www.uptodate.com/